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Translational approaches to understanding
resilience to Alzheimer’s disease
Sarah M. Neuner, 1 Maria Telpoukhovskaia, 2 Vilas Menon, 3 Kristen M.S. O’Connell, 2,4,5
Timothy J. Hohman, 6,7 and Catherine C. Kaczorowski 2,4,5,*
Individuals who maintain cognitive function despite high levels of Alzheimer’s
disease (AD)-associated pathology are said to be ‘resilient’ to AD. Identifying
mechanisms underlying resilience represents an exciting therapeutic opportunity.
Human studies have identiﬁed a number of molecular and genetic factors associated with resilience, but the complexity of these cohorts prohibits a complete
understanding of which factors are causal or simply correlated with resilience.
Genetically and phenotypically diverse mouse models of AD provide new and
translationally relevant opportunities to identify and prioritize new resilience
mechanisms for further cross-species investigation. This review will discuss
insights into resilience gained from both human and animal studies and highlight future approaches that may help translate these insights into therapeutics
designed to prevent or delay AD-related dementia.

Prevalence of resilience to Alzheimer’s neuropathology
AD is characterized clinically by a progressive loss of memory functions that impact daily life [1].
Dementia is preceded pathologically by progressive neurodegeneration, deposition of extracellular
beta amyloid (Aβ) aggregates, and intracellular accumulation of hyperphosphorylated tau-containing
neuroﬁbrillary tangles [2]. These proteinopathies are thought to be drivers of the neuronal dysfunction
and cognitive impairment that characterize the disease [3], in part due to the identiﬁcation of inherited
mutations in amyloid precursor protein (APP) that cause familial forms of autosomal dominant AD [4].
Despite the strong genetic link between amyloid and AD, a signiﬁcant proportion of individuals
with brain amyloid deposition remain non-demented throughout their lifespan [5]. These individuals are referred to in the literature as ‘resilient’ to AD pathology and represent a clinically interesting subset of the population, as they are able to cope with the presence of amyloid and/or tau
while escaping the deﬁcits typically associated with these pathological hallmarks. In large-scale
studies, up to one-third of elderly individuals are estimated to reach this criterion as measured
by either cerebrospinal ﬂuid (CSF) biomarker monitoring, amyloid- or tau-speciﬁc imaging techniques, or autopsy [6–8]. A better understanding of the mechanisms that confer protection
against cognitive decline in these individuals represents an outstanding therapeutic opportunity;
information gained from studying these ‘resilient’ individuals could provide the key to preventing
or delaying the onset of dementia in susceptible individuals. This review will primarily focus on
studies aimed at identifying cellular and molecular mediators of preserved cognition in the face
of amyloid and/or tau neuropathology. In addition, we will discuss how animal models can be
used to nominate, prioritize, and investigate potential therapeutic targets.

Features of resilient individuals
A number of deﬁnitions have been used in recent years to attempt to describe and understand
resilient individuals (Box 1 and Figure 1). A comprehensive histopathological study comparing
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Box 1. Deﬁning AD resilience
Generally, resilient individuals are those who evade cognitive decline associated with observed levels of amyloid and/or tau
neuropathology and/or inheritance of deleterious autosomal dominant AD mutations [74–76] (see Figure 1A,B in main
text). It has been hypothesized that these individuals exhibit higher levels of ‘cognitive reserve’, where functional brain processes are better able to cope with changes induced by neuropathology, or ‘brain reserve’, where variation in structural
characteristics of the brain (e.g., neuron or synapse numbers) increases the ability of an individual’s brain to deal with
neuropathological insults [77].
To understand the mechanisms and speciﬁc factors that differentiate resilient versus susceptible individuals, individuals
can be grouped into bins (e.g., non-demented with AD pathology versus demented with AD pathology). Historically, this
has been done postmortem using classiﬁcations from autopsy-based neuropathological scores on standardized scales
such as the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) score for neuritic plaques [78] and Braak
staging of neuroﬁbrillary tangles [79] in combination with antemortem scores on standardized cognitive tests.
Beyond discrete classiﬁcation systems, the development of approaches that deﬁne resiliency as a continuous metric has
been aided by the development of quantitative measurements of pathology, including CSF biomarkers, uptake of amyloidand tau-speciﬁc ligands measured via positron emission tomography (PET) imaging, and structural magnetic resonance
imaging (MRI) that quantiﬁes various metrics such as brain volume. The measures are aggregated to calculate a predicted
cognitive outcome given an individual’s measured pathology; this predicted value is compared with the same individual’s
actual cognitive performance. The discrepancy between the predicted and observed outcome, or the proportion of the
cognitive score not explained by neuropathology (i.e., the model residuals), is used to quantify an individual’s level of
resilience (see Figure 1B in main text). Nonresidual-based continuous metrics have also been developed [80], such as
the AD Cognitive Resilience (AD-CR) score. This score is computed using a global measure of cognition obtained proximal
to death and postmortem AD pathology. Machine learning algorithms trained using this information may eventually be able
to predict whether an individual will have an extremely high or low AD-CR score and thus be at extremely high or low risk for
progressing into AD dementia. Across these measures, individuals that perform better than predicted given an observed
level of pathology are said to have high resilience. The main beneﬁt of these approaches is that they do not exclude
individuals that do not ﬁt neatly into discrete bins but allow for interrogation of the entire study population.

pathology-positive non-demented individuals with AD cases and pathology-free controls found a
striking preservation of neuron numbers, synaptic markers, and axonal morphology in resilient
individuals compared with the demented cases [7] (Table 1). In addition, resilient individuals
exhibited a unique cytokine proﬁle consisting of higher levels of anti-inﬂammatory cytokines and
neurotrophins along with lower levels of chemokines associated with microglial recruitment and
activation [9]. Spine density was found to be signiﬁcantly reduced in AD patients relative to
both pathology-free controls and pathology-positive non-demented individuals [10], suggesting
maintenance of critical brain structures is an important determinant of maintained cognitive function in the face of pathology. Interestingly, studies have found that resilient individuals have lower
levels of hyperphosphorylated tau accumulation in the synaptic compartment [7] and neocortical
areas [11], despite comparable levels of amyloid. Across studies, tau pathology seems to be
more strongly linked to cognitive outcomes than amyloid pathology [12–14], suggesting resilience to tau pathology is less common than resilience to amyloid pathology.
Beyond discrete classiﬁcation systems, a number of studies have used a residual-based approach
to identify features common to resilient individuals (Box 1 and Table 1). For example, cortical thickness is associated with cognitive resilience to pathological tau [15], while younger age and higher
education was well correlated with resilience to structural changes and CSF/plasma-based
biomarker metrics [15–17]. An additional beneﬁt to studies that incorporate relatively noninvasive
measurements is their ability to be repeated over time. There is some evidence that resilience
capacity can change over time, with overall levels of resilience decreasing with age [18]. While
cross-sectional measures of residual-based resilience were indeed associated with cognitive
outcomes [19], there is some evidence that change in resilience metrics over time is even more
useful for predicting cognitive decline over time and identifying those individuals most at risk of
developing dementia [18], which is important for identifying when individuals stand to beneﬁt
most from early intervention and preventative-based therapeutics and clinical trials.
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Figure 1. Strategies to identify resilient individuals in human populations. (A) Example of a discrete classiﬁcation
system used to identify resilient individuals. In this classiﬁcation, each individual is assigned into one of the three groups:
cognitively unimpaired individuals, free from signiﬁcant Alzheimer’s disease (AD) pathology (left); AD patients, with brain
atrophy, amyloid plaques, and hyperphosphorylated tau tangles (middle); and ‘resilient’ individuals, with no apparent
cognitive impairment despite the presence of AD pathology (right). Preservation of brain volume and decreased
accumulation of tau tangles have been associated with resilience, although speciﬁc features of resilient individuals can vary
across studies and cohorts. (B) Resilient individuals can also be identiﬁed based on susceptibility to mutations typically
associated with increased risk for AD. A subset of the population is at relatively low genetic risk for AD and will exhibit
limited accumulation of AD pathology and has a high likelihood of remaining cognitively intact (left). Another subset will
inherit deleterious mutations associated with increased risk for AD: some of these individuals will go on to develop AD
pathology and dementia as expected (middle), while a resilient subset will remain cognitively intact throughout the lifespan
(right), despite varying levels of pathology. (C) Resilience can also be quantiﬁed as a continuous metric. In this approach,
diagnostic samples are ﬁrst collected and biomarkers are quantiﬁed (left). These measures are aggregated with other
demographic factors including, for instance, age, sex, and educational status, to predict an individual’s expected cognitive
(Figure legend continued at the bottom of the next page.)
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Targeted investigation of genetic and molecular mediators of resilience
Identiﬁcation of the speciﬁc genetic factors that promote resilience to AD pathology or autosomal
dominant familial AD mutations may provide a starting point for uncovering novel therapeutic
targets. Speciﬁc populations at high genetic risk for AD represent an opportunity to interrogate
mechanisms that enable some mutation carriers to ‘escape’ the predicted effect of the mutation
on cognitive outcomes. For example, a recent case study reported a carrier of a PSEN1 mutation
(PSEN1 E280A) who did not develop mild cognitive impairment until her seventies despite high
levels of amyloid [20]. Carriers of the PSEN1 E280A mutation exhibit an average age of dementia
onset at 49 years [21,22], so this individual seemed highly resilient to the typically deleterious
effects of the mutation [20]. This speciﬁc incidence of resilience was attributed to the presence
of a homozygous APOE variant known as the Christchurch mutation [23] that confers reductions
in low-density lipoprotein receptor and heparin binding [20], implicating these mechanisms as
putative drivers of resilience in the face of high amyloid deposition. The value of these pathways
as therapeutic targets remains to be elucidated, as the Christchurch mutation was also linked to
reduced tau pathology in the PSEN1 E280A carrier [20], which suggests some of the beneﬁts of
the mutation may be conferred through resistance to developing primary pathologies associated
with AD rather than true resilience as deﬁned earlier.
Populations at high genetic risk for AD provide several other important opportunities for the investigation of resilience. One approach, for instance, involved genome-wide searches for the modiﬁers of the age at onset of cognitive decline in families carrying what are typically considered highly
penetrant mutations. These studies have identiﬁed several putatively involved genes [24,25]
(Table 1). In addition, these populations provide the opportunity for targeted investigation into
hypothesized resilience factors such as BDNF. For example, it was found that an SNP in BDNF
(BDNFVal66Met) was associated with worsened neurodegeneration and cognitive decline given
amyloid pathology across individuals with autosomal dominant AD, studied as part of the
Dominantly Inherited Alzheimer Network (DIAN) cohort [26]. Individuals with APOE-ε4 genotype
provide a similar opportunity. Although APOE-ε4 has been identiﬁed as the most signiﬁcant
genetic risk factor for AD, some ε4 homozygous individuals do not develop AD as expected.
Several candidate genes (Table 1) have been associated with reduced AD risk in APOE-ε4positive individuals [27,28], highlighting these genes as potential therapeutic intervention points.
For example, levels of the soluble form of the AD risk gene TREM2 (sTREM2) found in the CSF
of biomarker-positive AD patients were found to signiﬁcantly modify the effect of an APOE-ε4
allele independent of primary AD pathology [29]. Higher CSF levels of sTREM2 were also found
to be associated with slower decline in memory and cognition in biomarker-positive AD patients
[30]. It is worth noting that some of the ‘resilience’ genes identiﬁed have also been associated with
reduced levels of pathology [31,32], highlighting the need to disentangle effects associated with
true resilience to pathology from resistance to developing these pathologies.

Genome-wide approaches to discover genetic and molecular mediators of
resilience
With the advent of more affordable genetic proﬁling, higher-throughput monitoring of relevant
biomarker metrics including CSF-, plasma-, and imaging-based metrics, as well as quantitative,
continuous metrics of resilience, whole-genome discovery-based studies of resilience are now
feasible. Here, residual resilience metrics are calculated across a population and treated as a

performance (prediction line in red). Results are then compared with the same individual’s actual cognitive performance, and
the discrepancy between these two values (i.e., the residual) is used to quantify resilience. Individuals with better than
predicted cognitive function (above red line) are said to exhibit high resilience, while those with worse than predicted
cognitive function (below red line) are said to exhibit low resilience.
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Table 1. Select factors correlated with resilience in humansa
Trait

Cohort

Directionality

Refs

Cortical thickness

Aβ-positive individuals with MCI
or dementia; residual metrics
used to deﬁne resilience

Increased thickness associated with cognitive resilience to tau
pathology

[15]

Spine density

AD patients vs. pathology-free
controls vs. pathology-positive,
non-demented controls

Spine density and numbers of thin and mushroom spines
reduced in AD cases only

[10]

Neuron numbers, synaptic markers

AD vs. pathology-free controls
vs. pathology-positive,
non-demented

Preservation of these features observed in pathology-positive
controls

[7]

Glial activation

AD vs. pathology-free controls
vs. pathology-positive,
non-demented

Lower activation in resilient individuals

[7]

Cortical proteins including NRN1,
EPHX4, SGTB, CPLX1

ROSMAP

Higher levels of these proteins associated with greater
resilience to several pathologies

[35]

REST protein levels

Pathology-positive controls vs.
AD patients

Nuclear REST levels higher in cognitively intact individuals

[53]

CSF levels of VEGF

ADNI

Elevated CSF VEGF associated with better cognitive outcomes
in pathology-positive individuals

[86]

IGFBP5, HSPB2, AK4, ITPK1 protein in
DLPFC

ROSMAP

IGFBP5, HSPB2, AK4 – higher protein levels associated with
faster cognitive function, opposite for ITPK1. Associations not
explained by neuropathology.

[87]

ENC1, UNC5C

ROSMAP

Multiomics approach (genetic, epigenetic, transcriptomic)
prioritized the aforementioned genes; increased UNC5C RNA
associated with worse residual-based resilience and increased
ENC1 associated with increased residual-based resilience

[33]

Cytokine proﬁles in entorhinal cortex
and superior temporal sulcus

Non-demented individuals with
(i) no, (ii) moderate, (iii) high
pathology and AD patients

Resilient cases had unique proﬁle – increased
anti-inﬂammatory cytokines, increased neurotrophic factors,
decreased microglial recruitment chemokines

[9]

sTREM2 levels in CSF

Subjects with AD deﬁned by CSF
biomarkers

Higher CSF sTREM2 associated with attenuated decline in
memory and cognition

[30]

MEF2C

Pathology-positive subjects with
or without AD dementia

Higher MEF2C observed in resilient individuals, speciﬁcally
within a subset of translationally active excitatory neurons

[38]

LAP3, MACROD1, SEMA7A protein in
synapse

Pathology-positive cognitively
intact ‘resilient’ patients vs. AD
patients

Resilient subjects had lower levels of these proteins in
synapses compared with AD patients

[37]

Proteins involved in serotonin release,
oxidative phosphorylation, glycolysis,
and proteasome function

Pathology-positive cognitively
intact ‘resilient’ patients vs. AD
patients

Resilient subjects had an enrichment for serotonin- and
oxidative phosphorylation-related proteins in the synapse, as
well as depletion of glycolysis- and proteasome-related
proteins in the synapse

[37]

APOE Christchurch mutation

PSEN1 E280A carrier

Homozygous mutation protected against high levels of
pathology

[20]

BDNF Val66Met mutation

DIAN, among others

Mutation associated with worsened neurodegeneration and
cognitive decline

[26,88–90]

Klotho haplotype VS

APOE-e4 positive individuals

One copy of haplotype lowered AD risk (but also reduced Aβ
and tau positivity on PET)

[28,31,32]

SNX25, PDLIM3, SORBS2

Caribbean Hispanics with PSEN1
p.G206A mutation

Association with age at onset in early- and late-onset AD

[24]

Gene variants near CD44, NPHP1,
CADPS2, GREM2

Families carrying PSEN1 E280A
mutation

Variants associated with age at onset of AD

[25]

Structural

Molecular

Genetic

(continued on next page)

Trends in Neurosciences, May 2022, Vol. 45, No. 5

373

Trends in Neurosciences
OPEN ACCESS

Table 1. (continued)
Trait

Cohort

Directionality

Refs

Gene variants near CASP7, SERPINA3

APOE-ε4 carriers

Variants associated with AD risk

Reviewed in
[27]

Variant upstream ATP8B1

Four cohorts: A4, ROSMAP,
ADNI, ACT

Variant associated with combined (i.e., cognitive and brain
structural based) resilience in cognitively intact subset of
patients

[17]

Variation at chromosome 8 locus

Mayo Clinic Study of Aging and
ADNI

Variant associated with differential cognitive resilience to brain
amyloid

[34]

Educational attainment

Various

Higher education is associated with increased resilience across
cohorts and studies

[15–17,91],
among
others

Early-life cognitive enrichment

MAP

Cognitive enrichment was associated with less cognitive
decline, 80% of the effect was independent of neuropathology

[92]

Lifestyle

a
Abbreviations: A4, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study; ACT, Adult Changes in Thought study; AD, Alzheimer’s disease; ADNI, Alzheimer’s
Disease Neuroimaging Initiative; DLPFC, dorsolateral prefrontal cortex; GWAS, genome-wide association studies; MCI, mild cognitive impairment; ROSMAP, Religious
Orders Study/Memory and Aging Project.

quantitative variable for association studies in order to identify speciﬁc variants, genes, proteins,
and/or pathways associated with the resilience phenotype [18]. As sample sizes are generally still
small compared with traditional case–control genome-wide association studies (GWAS), relatively few genome-wide signiﬁcant associations have been found [17,33,34]. Hits have been prioritized by combining genetic data with various additional functional omics datasets, including
methylation data and dorsolateral prefrontal cortex (DLPFC) RNA expression [33]. At the pathway
level, associations with resilience included amino acid metabolism, prolactin receptor signaling,
and the dehydrogenase pathway [17] as well as integrin-related cell adhesion and T-cell factor
signaling related to the Wnt/B-catenin pathway [34], nominating relatively broad biological categories for therapeutic intervention rather than speciﬁc therapeutic targets. Beyond genetic mediators of resilience, unbiased proteomics has identiﬁed cortical proteins strongly associated with
levels of resilience [35], including NRN1 (Table 1), which, similar to BDNF, is a neurotrophic factor
known to play important roles in synaptic function and plasticity as well as maintenance of axonal
morphology [36]. An additional study uniquely focused on synaptic proteins identiﬁed decreased
levels of proteins including MAP3 and SEMA7A in synapses from resilient individuals relative to
AD patients, as well as an overall enrichment for proteins involved in the serotonin release cycle
and oxidative phosphorylation and depletion of protein involved in glycolysis and proteasomerelated processes [37] (Table 1). Single-nuclear sequencing has also been used to identify a
resilience-related increase in MEF2C in a speciﬁc subpopulation of translationally active excitatory
neurons [38] (Table 1), demonstrating the utility of these high-dimensional and unbiased assays to
identify speciﬁc molecular mediators of resilience to AD pathology.

Using animal models to study resilience
While human-focused studies of resilience are crucial, drawbacks to these studies exist (Box 2),
calling for complementary research approaches. Model organism studies provide an important
resource to begin to address the outstanding questions surrounding resilience mechanisms
through longitudinal, mechanistic, and/or interventional studies with controlled environmental factors. Mice have emerged as a particularly useful model organism due to their affordability, shared
genetic features with humans, short generation time, and the vast array of mouse-speciﬁc genetic
engineering resources. As mice do not naturally develop AD, genetic engineering is necessary to
introduce human genes harboring mutations that lead to early-onset AD. These mutations
typically drive the overproduction of amyloid, which accumulates in the brain of these animals
374
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Box 2. Potential drawbacks to human-based studies of resilience
While both targeted and genome-wide studies identiﬁed correlates with resilience in the human population, it is important
to note several limitations of these types of analyses. Because brain tissue from individuals in these cohorts is not accessible during their lives, many studies use postmortem tissue to identify molecules (e.g., RNA, protein) that are associated
with performance on cognitive tests prior to death. However, in these studies, brain regions used to examine the molecular
mediators of resilience are typically selected based on already-known involvement in disease risk (e.g., hippocampus and
prefrontal cortex). It is possible that molecular changes that confer resilience originate in brain regions outside those classically affected in AD and are thus not typically selected for analyses. In addition, mechanisms and molecules important for
resilience are likely expressed and act well before the time at which these tissues can be accessed. This lack of access to
brain tissue early in the disease course is a signiﬁcant barrier to understanding the molecules most closely associated with
the onset of resilience (and/or dementia). In addition, the ability to test mechanistic hypotheses is generally limited in human
populations, as the identiﬁcation of molecules associated with cognitive outcomes is largely correlative [81]. Other potential
caveats and considerations, such as the limitations associated with retrospective group assignments, have been highlighted elsewhere [81]. Together, these factors have precluded a clear understanding of when in disease course and where
in the brain differences between resilient and susceptible individuals are ﬁrst detectable, a key piece of information that will
enable the eventual development of targeted therapeutics. These limitations create a critical need for innovative approaches to synergize the power of animal AD models with the wealth of medically relevant human data presently
available to parse out the spatial and temporal origins of resilience, as well as to establish causation and screen actionable
resilience interventions.

and induces AD-relevant symptoms including cognitive decline, synaptic dysfunction, and
neurodegeneration.
Historically, model organism studies have varied one condition in genetically identical individuals
(e.g., inbred mice) to evaluate the impact on disease outcomes. While many important insights
into disease pathogenesis have been achieved using this approach, recently the importance of
expanding model organism studies to include additional unique genotypes has been receiving
growing recognition. Speciﬁcally, genetic reference panels (GRPs) have emerged as a useful
tool to incorporate genetic diversity into mouse studies in a systematic way (Box 3). Another
notable development is that in addition to various forms of inbred lines, studies have begun to
incorporate genetic diversity in the form of outbred mice, particularly the Diversity Outbred (DO)
panel population of systematically outbred mice originating from the same eight founder strains
as the Collaborative Cross (CC) GRP [39].

Hypothesis-driven approaches to understanding mechanisms of resilience in
mouse models
Animal models offer opportunities to test the causality of resilience factors identiﬁed in human
studies. As mentioned previously, historically, this has often been performed in a single inbred
line where the intervention or treatment is the only factor being manipulated to assess causality
of the putative resilience factor. For example, viral delivery or overexpression of BDNF in various

Box 3. Mouse genetic reference panels
Two of the most well-characterized genetic reference panels (GRPs) are (i) the BXDs, named for the parental common inbred strains C57BL6J (B) and DBA2J (D) from which it is derived, and (ii) the Collaborative Cross (CC), derived from a systematic crossing scheme incorporating ﬁve common inbred strains and three wild-derived inbred strains [82]. In these
GRPs, mice with unique combinations of each parental genotype are inbred until a new stable inbred line is created.
The result is a large number of related inbred strains (the BXD GRP currently comprises 140 unique strains, while the
CC GRP contains ~70 strains), each of which can be reproducibly studied across time, laboratories, and under different
environmental conditions [72]. In addition, functional data such as transcriptional, proteomic, and behavioral proﬁles for
each strain can be collected, combined, and shared in order to better prioritize nominated candidates as described in
the main text for human data. GRPs allow for intense community collaboration, and a wealth of resources exist for each
system (e.g., GeneNetwork.orgiii [83], Systems-Genetics.orgiv [84], and the Mouse Phenome Databasev [85] allow for data
mining, visualization, and investigations of relationships between measures of interest). These resources enable investigation into the downstream effects of prioritized candidate genes and SNPs associated with traits of interest and facilitate the
identiﬁcation of relevant SNPs and molecular mechanisms from a large number of putative candidates.
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animal models of AD has been shown to improve outcomes, as assessed via various markers of
disease including hippocampal connectivity and cognitive tests, independent of any effects on
amyloid or tau neuropathology [40,41] (Table 2). Similarly, overexpression of Mef2 family
transcription factors in neurons of a mouse model of tauopathy was sufﬁcient to improve cognitive outcomes and rescue pathology-induced neuronal hyperexcitability without altering tau
pathology [38] (Table 2).
Beyond the testing of speciﬁc gene candidates, animal models also enable targeted experimental
investigation into pathways hypothesized to mediate resilience. In resilient patients, preservation
of dendritic spines is consistently observed, raising the question of what are the mechanisms and
pathways that preserve spines. Using cell and animal models, Aβ42-induced spine loss was
identiﬁed to be mediated, at least in part, through Rho-associated kinase ROCK2 and downstream activation of the kinase LIMK1 [42]. Treatment of AD model mice with a LIMK1 inhibitor
rescued Aβ-induced hippocampal spine loss and morphological aberrations [42]. In addition,
an intriguing observation across human populations is that despite similar levels of Aβ and tau,
men show worse cognition [43], greater cognitive decline [44], increased neurodegeneration
[45], and increased mortality [46] compared with women, suggesting an effect of sex on resilience
and reduced resilience in men. A study in transgenic animal models found that the presence of an
additional X chromosome either in males or females consistently improved Aβ-related mortality,
cognitive deﬁcits, and cellular viability [46]. The authors localized the protective effect to the
gene Kdm6a, a histone demethylase that escapes X chromosome inactivation and is enriched
in the brain. Overexpression of Kdm6a attenuated Aβ-induced neurotoxicity and cognitive

Table 2. Select factors associated with resilience in mouse modelsa
Trait

Cohort

Directionality

Refs

Intrinsic neuronal excitability

B6SJL 5XFAD

Decreased neuronal excitability in ‘weak-learners’

[50]

Pla2g4e expression and genotype

Tg2576

Increased Pla2g4e observed in ‘resilient’ mice

[51]

Synaptic protein levels

Tg2576

Increased in ‘resilient’ mice

[51]

Several gene networks, including
immune- and amyloid
degradation-related networks

Tg2576

Results suggest reduced CD4+ T cell inﬁltration in resilient mice

[49]

BDNF

J20 (amyloid transgenic) P301L
(tau transgenic) mouse models

Overexpression improved AD-related outcomes independent of
pathological changes

[40,41]

Mef2 family of transcription factors

P301S tauopathy model

Overexpression of Mef2a/c improved cognitive outcomes and
rescued neuronal hyperexcitability without changing tau pathology

[38]

Apoe genotype

AD-BXDs

D allele associated with worsened cognitive outcomes

[56]

Genetic risk score derived from
common AD risk genes

AD-BXDs

Genotype at common AD risk genes associated with late-life
cognitive outcomes

[56]

Several gene networks, including
vascular- and immune-related
networks

AD-BXDs

Higher expression of immune-enriched networks early in life
correlated with worse cognitive outcomes later in life, reverse was
true for expression of vascular-related networks

[57]

Variation at chromosome 2 locus

AD-BXDs

Genotype at identiﬁed locus regulated immune-related network
expression

[57]

X chromosome, putatively Kdm6a

Transgenically modiﬁed mice with
altered numbers of sex chromosomes
and hAPP model mice

Additional X chromosome in either males or females improved
Aβ-related mortality, cognitive deﬁcits, and cellular viability.
Overexpression of Kdm6a, which escapes X inactivation, was
sufﬁcient to recapitulate this effect in cell and animal models

[46]

a
Abbreviations: 5XFAD, common AD transgene incorporating ﬁve mutations known to cause familial AD in humans; AD, Alzheimer’s disease; AD-BXDs, F1 genetic reference
panel generated by introducing the 5XFAD transgene into the BXD panel (see Box 3 for details); B6SJL, mixed background strain derived from the inbred strains C57BL6/J
and SJL/J; BDNF, brain-derived neurotrophic factor.
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impairment in both cell and animal models [46], nominating Kdm6a as a putative mechanistic
driver of resilience.

Exploiting phenotypic diversity to identify resilience mechanisms
Beyond mechanistic investigation of previously identiﬁed resilience factors [40,41,47], mouse
models also provide a powerful tool to investigate differential susceptibility to typically highly deleterious AD mutations – similar to the approach described previously using families harboring autosomal dominant AD mutations (Figure 2). In animal model studies, various studies have shown
that even within a single inbred strain, mice are not uniformly susceptible to the cognitive effects of
amyloid and/or tau accumulation [48–51]. For example, two independent groups found that
when mice are subjected to paradigms meant to measure learning and memory, age-matched
AD mice could be divided into either ‘weak-learner’ or ‘strong-learner’ subsets [49–51]. Across
studies, whether a particular mouse exhibited cognitive deﬁcits was not signiﬁcantly associated
with amyloid plaque density, levels of tau hyperphosphorylation, or markers of glial activation,
suggesting that the ‘strong-learners’ were exhibiting resilience to neuropathology [50,51]. The
identiﬁcation of these independent subsets provides an opportunity to investigate causal mechanisms driving resilience. In the case of Tg2576 transgenic mice, resilient animals exhibited higher
levels of synaptic proteins, suggesting preserved synaptic function [51] (Table 2). Similarly, resilient mice carrying the 5XFAD transgene exhibited a higher degree of learning-related intrinsic neuronal plasticity relative to 5XFAD weak-learners [50] (Table 2). Together, these studies highlight
(A)

(B)

Trends in Neurosciences

Figure 2. Exploiting phenotypic or genetic diversity in mouse populations to investigate molecular and genetic
mediators of resilience. (A) Phenotypic diversity among genetically homogenous strains of mice harboring Alzheimer’s
disease (AD) transgenes can be harnessed to classify individuals into discrete ‘high resilience’ (i.e., strong-learner) or
‘low resilience’ (i.e., weak-learner) categories. Pathology can be quantiﬁed using a range of techniques including
immunohistochemistry to account for differences in amyloid and/or hyperphosphorylated tau accumulation. (B) Traditional
animal models do not incorporate genetic diversity, which in human populations contributes to differing levels of resilience.
By introducing AD transgenes into diverse models including the BXDs, Collaborative Cross, or Diversity Outbred panels,
strain-by-strain differences in cognitive outcomes and pathology can be quantiﬁed and used for genetic mapping in order
to identify speciﬁc genetic mediators of resilience.
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maintenance of synaptic structure and neuronal excitability as an important mechanism mediating resilience to AD pathology. Transcriptomic analysis comparing Tg2576 resilient and susceptible mice identiﬁed the gene Pla2g4e (phospholipase A2 group IVE) as a putative driver of
resilience [51]. Subsequent overexpression of Pla2g4e in hippocampal neurons of AD mice
was sufﬁcient to completely restore cognitive function and increase spine number without affecting amyloid or tau pathology [51]. In addition, PLA2G4E was found to be decreased in the brains
of late-stage AD human patients, suggesting this approach identiﬁed a translationally relevant
therapeutic target. A similar transcriptomic analysis also identiﬁed several additional pathways
putatively involved in resilience and predicted a reduced inﬁltration of peripheral immune cells
into the brains of resilient mice [49]. A previous investigation into the hippocampal membrane proteome of 5XFAD strong-learners and weak-learners identiﬁed several putative drivers of resilience, including the epigenetic modiﬁer REST [52] previously associated with resilience to
pathology in human populations [53] (Table 2). Together, these ﬁndings demonstrate the powerful translational potential of harnessing variable AD susceptibility in animal models.

Exploiting genetic diversity to identify resilience mechanisms
Traditionally, animal model studies of resilience to AD have often relied on experiments within a single strain. While variable susceptibility within a single strain provides important mechanistic insight
into resilience, focusing on a single strain leads to a scenario that is distant from the degree of genetic diversity of human populations. Comparison of genetically distinct mouse strains harboring
identical amyloid- or tau-overexpressing transgenes has conﬁrmed the presence of variable susceptibility across strains to disease outcomes including pathological burden and overall survival
[48,54,55]. To speciﬁcally use GRPs (Box 3) to identify resilience factors, a new F1 mouse population was generated by introducing the well-established 5XFAD transgene into almost 30 BXD
strains [56]. This panel, referred to as the AD-BXDs, was thoroughly characterized for a variety of
disease-relevant traits, including amyloid deposition and cognitive decline. As hypothesized, a
wide range of cognitive outcomes was observed across the strains despite similar levels of amyloid
pathology [56], demonstrating differing levels of cognitive resilience depending on an individual
strain’s genetic makeup. Notably, genotype at well-deﬁned late-onset AD risk factors including
Apoe, Bin1, and Clu, among others, inﬂuenced cognitive outcomes in the AD-BXDs, suggesting
this novel panel represents a resource with high translational potential [56] (Table 2). Of note, the
single Apoe mutation segregating across the AD-BXDs occurs near the receptor-binding region
of the protein, where the highly protective Christchurch mutation occurs in human populations.
This suggests that the AD-BXDs, in addition to their utility in identifying modiﬁers of familial AD,
could be useful for identifying more general modiﬁers of late-onset AD susceptibility.
The reproducible nature of an F1 GRP design provides an opportunity to understand genetic and
molecular drivers of resilience. Speciﬁcally, transcriptional networks present early in life, at a time
point at which the AD-BXDs were not impaired as a population relative to their wild-type littermates, were related to strain-speciﬁc cognitive outcomes in later life [57]. Networks related to
neuroinﬂammation, brain vasculature, extracellular matrix organization, and synaptic signaling
were associated with cognitive resilience in this population [57], mirroring some of the pathways
(e.g., vascular risk, synaptic structure) important in regulating human resilience (Table 2) and highlighting these as mechanisms that may drive resilience. Due to the genetic structure of the ADBXDs, genetic mapping can be used to identify speciﬁc regions associated with traits of interest.
A region on chromosome 2 was identiﬁed as containing variants that directly modulate expression of identiﬁed resilience networks in AD-BXD mice [57]. Interestingly, the human equivalent
of this region was also associated with age at AD onset in familial AD studies [58,59], further demonstrating the translational relevance of this panel for identifying drivers of resilience that may be
harnessed for future therapeutic development. Notably, beyond speciﬁc resilience to AD
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pathology, the AD-BXDs can also be combined with their wild-type or non-transgenic littermates
(i.e., the Ntg-BXDs) to understand and identify mechanisms that promote cognitive longevity
across disease and normal aging [60,61].

Future directions for animal studies of resilience
Translating ﬁndings from animal models to the human condition is not without challenges. For example, microglia, the resident immune cells of the brain, have been identiﬁed as cells involved in
disease progression [62]. However, signiﬁcant differences exist between the mouse and human
immune systems, and these could translate into marked differences in the microglial response to
amyloid [63]. In addition, most transgenes used to study AD in mouse models overexpress
human mutant APP and PSEN1 in a cell-type-speciﬁc manner. In humans, mutations are presumably expressed in all cell types, so the expression of transgenes only in a single cell type, typically neurons, prohibits the identiﬁcation of how these mutations may drive disease through
effects on intercell communication or non-neuronal mechanisms. Newer models incorporating
AD mutations directly into the mouse orthologs have not replicated all ﬁndings in earlier transgenic
models, raising the concern that some aspects of disease in these mice are driven purely by overexpression artifacts rather than mutation status [64]. Finally, most of the widely used animal
models of AD produce no detectable tau pathology. This is primarily because variants in the
gene encoding for tau, MAPT, have not been genetically associated with AD and were therefore
thought not to be a valid way to genetically model AD in the mouse. However, because tau
pathology is part of the diagnostic criteria for AD, models that incorporate some degree of tau
pathology likely come closer to recapitulating the human disease. A recent study identiﬁed the
MEF2 family of transcription factors as potential mediator(s) of resilience to tau pathology with
high translational relevance, demonstrating the utility and potential of this approach [38]. As
such, incorporating tau pathology into future studies of resilience to AD will be critical. For example, the AD-BXD reference panel could be regenerated using alternative AD models harboring tau
mutations. This approach could provide important insight into the overlap or discordance
between the genetic mediators of resilience to amyloid or tau pathology. Importantly, as tau
pathology appears to be more intimately coupled to cognitive outcomes than amyloid in human
populations, understanding the genetic mechanisms that enable resilience to tau pathology may
provide the most broadly applicable therapeutic targets.
While the BXD family contains six million SNPs [65], this degree of genetic diversity does not reach
what is observed across the human population. By contrast, the wild-derived strains used to generate the CC and DO panels harbor almost 40 million SNPs relative to the reference C57BL6J genome [39]. Introduction of AD transgenes into these wild-derived strains themselves produces a
wide variation in amyloid deposition, neuronal cell loss, and microglial morphology and activation
[66,67]. Similar to the approach used to generate the AD-BXDs discussed earlier, future studies
incorporating AD transgenes into CC strains could provide insights into which, if any, CC strains
exhibit cognitive resilience to amyloid deposition and could offer opportunities to identify novel
resilience factors that may not exhibit genetic variation in the BXD GRP. The areas of oncology
and immunology offer some precedents in that regard: the introduction of disease-causative
transgenes into the DO population has proven useful in identifying mediators of prostate cancer
[68] and immune dysfunction [69,70]. Possibly, the DO panel may prove similarly useful in nominating speciﬁc genetic resilience candidates. Encouraging data pointing in this direction are the
differential resilience to normal cognitive aging in the DO panel, driven by genotype at Dlgap2
and presumably subsequent alterations in spine morphology [71].
Laboratory mice also provide a unique opportunity to begin to understand the mechanisms by
which various lifestyle factors may contribute to resilience [72]. Because of the well-deﬁned
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environment in which laboratory mice are housed, researchers can systematically vary a single lifestyle factor, such as diet, physical activity, or cognitive enrichment. The effect of each of these
well-deﬁned manipulations on cognitive outcomes can then be interrogated and mechanisms can
be investigated, providing insight into how each of these interventions may inﬂuence disease outcomes. There is abundant evidence that environmental enrichment and physical activity improve disease outcomes in animal models of AD [73], but most of these studies have been conducted only in
single inbred strains. Given that genetic heterogeneity may inﬂuence the effects of these interventions, it would be valuable to pair these approaches with genetically diverse models [72]. These approaches may also help identify speciﬁc human populations that stand to beneﬁt most from certain
lifestyle interventions, providing a pathway to personalized recommendations to promote resilience.
Finally, future studies utilizing genetically diverse animal models should continually strive to
complement their ﬁndings with human data in order to maximize their translational relevance.
Due to the combination of increased availability of large-scale human datasets and increased
collaboration through consortia such as the Collaboratory on Research Deﬁnitions for Reserve
and Resilience in Cognitive Aging and Dementiai and Resilience-ADii, it has become increasingly
possible to perform cross-species analyses. Often, human studies that aim to identify resilience
mediators by testing many genes or variants for association with cognitive function simultaneously suffer from low power due to low sample size and high statistical burden. Using prior
knowledge gained from animal studies to test speciﬁc variants or genes for association with cognitive function in humans, rather than performing genome-wide searches, enables researchers to
nominate new resilience mediators that may have been previously overlooked in these complex
studies. It is worth noting that the approaches described here to understand resilience to AD,
including incorporating genetic and phenotypic diversity across animal models of disease, are
broadly applicable to a range of complex diseases. As these studies require large numbers of
animals and phenotyping tests, and also generate large amounts of data, the continued development of high-throughput tools (e.g., automated behavioral assays, imaging, and biomarker
analysis platforms) will be essential for effective progress.

Concluding remarks
Understanding how some individuals can retain cognitive function despite high levels of neuropathology is critical for developing therapeutics to prevent or delay the onset of dementia in the
larger population. Initial studies have identiﬁed several factors that contribute to resilience to AD
pathology, including the ability to maintain brain synapse structure and functional connectivity,
potentially through the maintenance of neurotrophic factors including NRN1 and BDNF. Recent
advances in the ability to quantitatively deﬁne resilience across large populations, in combination
with relatively noninvasive CSF/plasma biomarkers and structural imaging measurements, have
facilitated the search for genetic contributors to resilience.
To facilitate the identiﬁcation of actionable resilience factors, a major goal for future work is to better understand which brain regions are involved, and at what time point in disease progression
resilience mechanisms act (see Outstanding questions). This will necessitate brain-wide assessment at various time points throughout the lifespan, in contrast to proﬁling a single region with a
single technology (e.g., PFC- and hippocampus-speciﬁc RNA sequencing). Understanding
where in the brain (or body) resilience originates, when in the disease course it emerges, and
how it progresses with age will provide critical insight for the development of effective therapies.
Each of these questions can be systematically addressed when paired with both comprehensive
human data and innovative mouse models that harness genetic complexity under well-deﬁned
environmental conditions. With these techniques, the ﬁeld is hopefully well positioned to identify
new avenues for therapeutic development in the coming years.
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Outstanding questions
Quantifying resilience as a continuous
metric eliminates the need to
‘discard’ data from patients that do
not ﬁt into discrete classiﬁcation
bins. This perspective, combined
with noninvasive techniques to
evaluate AD pathology, allows performing large-scale analyses of the
genetic and molecular mediators of
resilience. Will the use of larger cohorts result in the identiﬁcation and
prioritization of novel mediators of resilience to AD pathology?
Previous studies identiﬁed candidate
features of resilience. Can these
various metrics be integrated to
identify individuals who may have low
levels of innate resilience and thus be
at a higher risk for developing
dementia due to AD? Can this
information be used to begin early
intervention and/or optimize clinical
trial enrollment? Is early intervention
necessary, or can treatments which
intervene after the onset of cognitive
decline be effective?
While the use of the BXD genetic reference panel improved translational relevance of AD mouse models, the
genetic diversity present in this panel
does not approach the diversity present in the human population. Will the
introduction of AD transgenes into
more complex animal models of genetic diversity (i.e., CC, DO – Box 3)
yield new insights into mediators of
resilience?
As tau pathology is more closely linked
to cognitive outcomes than amyloid
and is a diagnostic criterion for AD, is
inclusion of tau pathology necessary
to identify translationally relevant mediators of resilience? What is the best
translationally relevant model(s) for preclinical studies of therapeutic targets?
The exact brain region(s) and
molecular mediator(s) for conferring
enhanced resilience to AD pathology
remain unclear. Can brain-wide studies designed to survey putative mediators at multiple levels (i.e., DNA, RNA,
protein) help pinpoint which brain regions or molecules may be most highly
associated with resilience? In addition,
when do ‘resilient’ and ‘susceptible’ individuals ﬁrst start to deviate?
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